关注
Neil Osheroff
Neil Osheroff
Professor of Biochemistry, Vanderbilt University School of Medicine
在 Vanderbilt.Edu 的电子邮件经过验证
标题
引用次数
引用次数
年份
Mechanism of quinolone action and resistance
KJ Aldred, RJ Kerns, N Osheroff
Biochemistry 53 (10), 1565-1574, 2014
14212014
Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme
DA Burden, N Osheroff
Biochimica et Biophysica Acta (BBA)-Gene Structure and Expression 1400 (1-3 …, 1998
7911998
Topoisomerase Poisons: Harnessing the Dark Side of Enzyme Mechanism (∗)
SJ Froelich-Ammon, N Osheroff
Journal of Biological chemistry 270 (37), 21429-21432, 1995
7441995
Etoposide, topoisomerase II and cancer
EL Baldwin, N Osheroff
Current Medicinal Chemistry-Anti-Cancer Agents 5 (4), 363-372, 2005
6722005
In situ localization of DNA topoisomerase II, a major polypeptide component of the Drosophila nuclear matrix fraction.
M Berrios, N Osheroff, PA Fisher
Proceedings of the National Academy of Sciences 82 (12), 4142-4146, 1985
6721985
The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing
JE Deweese, N Osheroff
Nucleic acids research 37 (3), 738-748, 2009
5492009
DNA topoisomerase II, genotoxicity, and cancer
AK McClendon, N Osheroff
Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 623 (1 …, 2007
5222007
Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice
JM Fortune, N Osheroff
Academic Press 64, 221-253, 2000
5182000
DNA topoisomerase II from Drosophila melanogaster. Relaxation of supercoiled DNA.
N Osheroff, ER Shelton, DL Brutlag
Journal of Biological Chemistry 258 (15), 9536-9543, 1983
4161983
Biochemical basis for the interactions of type I and type II topoisomerases with DNA
N Osheroff
Pharmacology & therapeutics 41 (1-2), 223-241, 1989
3881989
DNA topoisomerase II in therapy-related acute promyelocytic leukemia
AR Mistry, CA Felix, RJ Whitmarsh, A Mason, A Reiter, B Cassinat, ...
New England Journal of Medicine 352 (15), 1529-1538, 2005
3442005
Merbarone inhibits the catalytic activity of human topoisomerase IIα by blocking DNA cleavage
JM Fortune, N Osheroff
Journal of Biological Chemistry 273 (28), 17643-17650, 1998
3411998
Catalytic function of DNA topoisomerase II
N Osheroff, EL Zechiedrich, KC Gale
BioEssays 13 (6), 269-275, 1991
3381991
Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide
N Osheroff
Biochemistry 28 (15), 6157-6160, 1989
3371989
Eukaryotic topoisomerases recognize nucleic acid topology by preferentially interacting with DNA crossovers.
EL Zechiedrich, N Osheroff
The EMBO journal 9 (13), 4555-4562, 1990
3271990
Phosphorylation of DNA topoisomerase II by casein kinase II: modulation of eukaryotic topoisomerase II activity in vitro.
P Ackerman, CV Glover, N Osheroff
Proceedings of the National Academy of Sciences 82 (10), 3164-3168, 1985
3001985
Eukaryotic topoisomerase II. Characterization of enzyme turnover.
N Osheroff
Journal of Biological Chemistry 261 (21), 9944-9950, 1986
2941986
When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs
AH Corbett, N Osheroff
Chemical Research in Toxicology 6 (5), 585-597, 1993
2931993
Topoisomerase II and leukemia
MJ Pendleton, RH Lindsey Jr, CA Felix, D Grimwade, N Osheroff
Annals of the New York Academy of Sciences 1310 (1), 98-110, 2014
2402014
Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes
AM Wilstermann, N Osheroff
Current topics in medicinal chemistry 3 (3), 321-338, 2003
2302003
系统目前无法执行此操作,请稍后再试。
文章 1–20